Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held biotechnology company headquartered in London, UK. The acquisition ...

Sanofi is buying U.K. biotechnology company Vicebio for up to $1.6 billion in a deal that seeks to strengthen the French drugmaker's portfolio of respiratory vaccines and leave pipeline setbacks ...

Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025. Sanofi announced today that it has entered into an ...

Sanofi is shelling out $1.15 billion to acquire Vicebio, a startup with a pipeline of respiratory vaccine candidates and a platform technology that will support the pharmaceutical giant’s ambitions to ...

Sanofi agreed to buy vaccine specialist Dynavax Technologies in a $2.2 billion cash deal, turning to dealmaking in a bid to move past pipeline setbacks. The French pharmaceutical company announced the ...

In the race to develop next-generation respiratory virus vaccines, French pharmaceutical company Sanofi has agreed to buy Vicebio Ltd., a privately-held biotechnology company headquartered in London, ...

Pipeline setback and oncology approval reshape the story Sanofi (ENXTPA:SAN) has just had a mixed week, pausing its phase 3 riliprubart MOBILIZE trial in chronic inflammatory demyelinating ...